Peer-reviewedCC BYCancers
Plasma Carrier Proteins as Supramolecular Nanovectors for Cancer Therapy: The Trojan Horse Approach
- 1Preclinical & Translational Research in Oncology Lab (PRO), IRCCS Azienda Ospedaliero—Universitaria di Bologna, 40138 Bologna, Italy; (A.M.); (A.C.); (M.D.G.)
Related
- Safety of PCV13 with Different Carrier Proteins (CRM197, TT, and TT/DT) — Jiangsu Province, China, 2022–2024
- Glycometabolic, inflammatory and exocrine plasma proteins predict cancer in individuals with cardiovascular disease
- Hemophilia: Carrier testing and therapy
- Analysis of the Potential Mediating Role of Plasma Proteins in the Association Between Air Pollution Exposure and Lung Cancer Risk Among Ever-Smokers
- Causal association between plasma vascular endothelial growth factor family proteins and placenta previa: A 2-sample Mendelian randomization study.
BibTeX
@article{marconi2026plasma,
title = {{Plasma Carrier Proteins as Supramolecular Nanovectors for Cancer Therapy: The Trojan Horse Approach}},
author = {Alessia Marconi and Andrea Carboni and Matteo Di Giosia and Matteo Calvaresi},
journal = {Cancers},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13663963},
note = {CC BY},
}
RIS
TY - JOUR
TI - Plasma Carrier Proteins as Supramolecular Nanovectors for Cancer Therapy: The Trojan Horse Approach
AU - Alessia Marconi
AU - Andrea Carboni
AU - Matteo Di Giosia
AU - Matteo Calvaresi
PY - 2026
DA - 2026/09/24
JO - Cancers
UR - https://europepmc.org/article/PMC/PMC13663963
SN - 2072-6694
ER -